NCT01337765View on ClinicalTrials.gov

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 8, 2011

Primary Completion Date

March 22, 2013

Study Completion Date

March 22, 2013

Conditions
Unspecified Adult Solid Tumor, Protocol SpecificSolid Tumor
Interventions
DRUG

BEZ235 + MEK162

Trial Locations (6)

3050

Pfizer Investigative Site, Parkville

94805

Pfizer Investigative Site, Villejuif

02114

Massachusetts General Hospital Mass General 2, Boston

77030-4009

University of Texas/MD Anderson Cancer Center MD Anderson PSC, Houston

M5G 2M9

Pfizer Investigative Site, Toronto

08035

Pfizer Investigative Site, Barcelona

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY